Frequently asked questions
The global controlled substance market was valued at USD 66845.9 Million in 2022.
The controlled substance market is expected to grow at a CAGR of 7.5% between 2023 and 2030, reaching USD 119218.2 Million in 2030.
Pain management is the leading segment by therapeutic use, holding over 32% share in value in 2022.
The hospital pharmacies segment governs the global demand for controlled substances, holding a massive share of over 35% in 2022.
The substance use disorder segment will post the highest CAGR over the projection period.
With more than one-third of the market in 2022, North America is driving the expansion of the controlled substance industry.
The top players include Johnson & Johnson, Pfizer, Sanofi, Merck & Co., Gilead Sciences, Amgen, Novartis, AbbVie, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva Pharmaceutical, Bayer, Novo Nordisk, Allergan, Takeda Pharmaceutical, Boehringer Ingelheim, Aspen Pharmacare, Astellas Pharma, and Others.
The major market drivers of the controlled substance industry include the rising prevalence of chronic pain and related conditions and ongoing pharmaceutical innovations and research.
The major market restraints of the controlled substance industry are stringent regulatory frameworks & compliance burdens and the stigmatization and negative public perception surrounding the use of controlled substances.
The major market opportunities of the controlled substance industry encompass advancements in telemedicine and digital health solutions and the research and development of non-opioid alternatives and novel formulations for pain management.